

— OFFICIALLY LICENSED —

# BEST OF ASCO®

2017 ANNUAL MEETING



Organized by **Lebanese Society of Medical Oncology**  
In collaboration with **Jordanian Oncology Society**  
Licensed by **The American Society of Clinical Oncology**



.....  
**July 14 - 15, 2017**

Phoenicia Hotel , Beirut - Lebanon

## Dear Colleagues,

The Lebanese Society of Medical Oncology have been organizing, under licensure from ASCO, an annual Best of ASCO meetings since 2006.

The meeting has been a great place to attend presentations of the latest advances and practice-changing cancer research results.

Physicians from Lebanon and the Region, come for listening, discussing, networking and socializing with their colleagues, and also taking a break and enjoying good time in Beautiful Lebanon.

At Best of ASCO, you get more than out of ASCO itself.

During the span of 2 days, a group of International and Regional Experts will present to you a selection of the most highly rated abstracts, Late-Breaking Abstracts, Clinical Science Symposia and Plenary Session presentations.

This year, we will hold the meeting in collaboration with Jordanian Oncology Society to unite our efforts to spread knowledge and help our patients everywhere in the region.

*Welcome to our 12th Best of ASCO – Lebanon 2017*

**Dr. Joseph Makdessi**  
Co-Chair 12th Best of ASCO



**Dr. Nagi El Saghir**  
Co-Chair 12th Best of ASCO



**Dr. Sanaa Sukhun**  
Co-Chair 12th Best of ASCO



## 12<sup>th</sup> Best of ASCO Lebanon

July 14 - 15, 2017 - Phoenicia Hotel, Beirut - Lebanon

Organized by LSMO (Lebanese Society of Medical Oncology)

In collaboration with JOS (Jordanian Oncology Society)

Licensed by ASCO (American Society of Clinical Oncology)

Endorsed by AMAAC (Arab Medical Association Against Cancer)

### Co-Chairs:

Joseph Makdessi, MD

Sana Al-Sukhun, MD

Nagi El Saghir, MD, FACP

### Planning Committee:

Sana Al-Sukhun, MD

Adnan Atallah, MD

Nizar Bitar, MD

Nagi El Saghir, MD

Oussama Jradi, MD

Joseph Makdessi, MD

Arafat Tfayli, MD

## Friday July 14, 2017

### 09:00 - 09:40 Head & Neck Cancers

*Speakers: Fadlo Khuri, MD - Issa Mouhammed, MD - Arafat Tfayli, MD*

*Chairs: Sami Khatib, MD - Nader Al-Bsoul, MD - Roger Moukarbel, MD - Anthony Hawat, MD*

▪ **Abstract 6000:** Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.

*Athanassios Argiris - Presented by Issa Mouhammed, MD*

▪ **Abstract 6002:** A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT)

*Anthony Chan - Presented by Fadlo Khuri, MD*

▪ **Abstract 6007:** Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.

*Vanita Noronha - Presented by Arafat Tfayli, MD*

### 09:40 - 10:20 Lung Cancer - Non-small Cell/ Metastatic

*Speakers: Fadlo Khuri, MD - Taher Abu Hijlah, MD - Arafat Tfayli, MD*

*Chairs: Abdulmajeed Dayyat, MD - Anthony Saroufim, MD - Pierre Sfeir, MD*

▪ **Abstract 9000:** Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS)  $\geq$ 50% enrolled in KEYNOTE-024.

*Julie Brahmer - Presented by Fadlo Khuri, MD*

▪ **Abstract 9004:** Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

*Jaafar Bennouna - Presented by Taher Abu Hijlah, MD*

▪ **Abstract LBA9007:** Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

*Tony Mok - Presented by Arafat Tfayli, MD*

▪ **Abstract LBA9008:** Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

*Alice Shaw - Presented by Arafat Tfayli, MD*

## Friday July 14, 2017

### 10:20 - 11:00 Lung Cancer - Non-small Cell Local-Regional / Small Cell / Other Thoracic Cancers

*Speakers: Fadlo Khuri, MD - Hazem Assi, MD*

*Chairs: Sami Rabadi, MD - Ali Monzer, MD - Fady Geara, MD*

▪ **Abstract 8500:** Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIa (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).

*Yi-Long Wu - Presented by Fadlo Khuri, MD*

▪ **Abstract 8503:** Nivolumab (nivo)  $\pm$  ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

*Matthew Hellmann - Presented by Fadlo Khuri, MD*

▪ **Abstract LBA8507:** Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

*Arnaud Scherpereel - Presented by Hazem Assi, MD*

### 11:00 - 11:15 COFFEE BREAK

### 11:15 - 12:00 Gastrointestinal (Colorectal) Cancer

*Speakers: Ali Shamseddine, MD - Belal Alhawwari, MD - Sally Temraz, MD*

*Chairs: Salah Halasseh, MD - Osama Hamed, MD - Fadi Nasr, MD*

▪ **Abstract LBA1:** Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy).

*Qian Shi - Presented by Ali Shamseddine, MD*

▪ **Abstract 3503:** Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

*Alan Venook - Presented by Sally Temraz, MD*

▪ **Abstract 3505:** Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

*Scott Kopetz - Presented by Sally Temraz, MD*

▪ **Abstract 3507:** Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.

*Ricky Sharma - Presented by Belal Alhawwari, MD*

## Friday July 14, 2017

### 12:00 - 13:00 Gastrointestinal (Noncolorectal) Cancer

*Speakers: Ali Shamseddine, MD - Khulood AlQasem, MD - Fadi Farhat, MD*

*Chairs: Mohamad Khalifeh, MD - Jehad Al Maani, MD - Tareq Al-Jabari, MD - Wajdi Daou, MD*

▪ **Abstract 4001:** Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

*Ann-Lii Cheng - Presented by Fadi Farhat, MD*

▪ **Abstract 4006:** Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.

*John Primrose - Presented by Ali Shamseddine, MD*

▪ **Abstract 4007:** Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.

*Howard Safran - Presented by Khulood AlQasem, MD*

▪ **Abstract 4014:** Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

*Yelena Janjigian - Presented by Fadi Farhat, MD*

### 13:00 - 14:00 LUNCH BREAK

### 14:00 - 15:00 Educational Session: PANEL gene testing for risk management /Optimizing endocrine therapy and side effect management

*Presented by Nagi El Saghir, MD, Joseph Makdessi, MD, Sana Al-Sukhun, MD*

### 15:00 - 15:45 Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

*Speakers: Ahmad Ibrahim, MD - Ziad Salem, MD*

*Chairs: Nabeel Alowsh, MD - Hadi Ghanem, MD - Oussama Jradi, MD*

▪ **Abstract 7500:** First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.

*Ian Flinn - Presented by Ziad Salem, MD*

▪ **Abstract 7503:** A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/ antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).

*Amy Ruppert - Presented by Ahmad Ibrahim, MD*

▪ **Abstract 7506:** Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

*Michael Pfreundschuh - Presented by Ahmad Ibrahim, MD*

### 15:45 - 16:00 COFFEE BREAK

## Friday July 14, 2017

### 16:00 - 16:30 Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant

*Speakers: Nizar Bitar, MD - Jean Cheikh, MD - Marcel Massoud, MD*

*Chairs: Mohammad Dweiri, MD - Therese Abi Nasr, MD - Joyce Habib, MD*

▪ **Abstract 7000:** Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).

*Ruben Mesa - Presented by Marcel Massoud, MD*

▪ **Abstract 7002:** Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

*Jorge Cortes - Presented by Nizar Bitar, MD*

▪ **Abstract 7006:** Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial.

*Richard Ambinder - Presented by Jean Cheikh, MD*

### 16:30 - 17:00 Hematologic Malignancies - Plasma Cell Dyscrasia

*Speakers: Samir Yasser, MD - Khaled Ibrahim, MD - Ghazi Nsouli, MD*

*Chairs: Adnan Atallah, MD - Mona Ayoubi, MD - Rabih Said, MD*

▪ **Abstract 8000:** Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

*Andrzej Jakubowiak - Presented by Khaled Ibrahim, MD*

▪ **Abstract 8003:** Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).

*Francesca Maria Gay - Presented by Samir Yasser, MD*

▪ **Abstract 8005:** Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.

*Noopur Raje - Presented by Ghazi Nsouli, MD*

### 17:00 - 17:30 OPENING CEREMONY

### 20:00 GALA DINNER



## Saturday July 15, 2017

### 09:00 - 09:30 Gynecologic Cancer

*Speakers: Muhieddine Seoud, MD - Imad Jaradat, MD*

*Chairs: Issam Latayfeh, MD - Adnan Qasem, MD - David Atallah, MD - Elie Nasr, MD*

▪ **Abstract 5502:** Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

*Stephanie De Boer - Presented by Muhieddine Seoud, MD*

▪ **Abstract 5505:** A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

*Daniela Matei - Presented by Muhieddine Seoud, MD*

▪ **Abstract 5506:** Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.

*Jonathan Ledermann - Presented by Imad Jaradat, MD*

### 09:30 - 10:30 Breast Cancer - Local / Regional / Adjuvant

*Speakers: Ahmad Awada, MD - Sana Al-Sukhun, MD - Jaber Abbas, MD*

*Chairs: Jamal Masaad, MD - Imad El Hajj, MD - Jawad Makarem, MD - Nagib Geahchan, MD*

▪ **Abstract LBA500:** APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).

*Gunter Von Minckwitz - Presented by Ahmad Awada, MD*

▪ **Abstract 506:** Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

*Rita Nanda - Presented by Ahmad Awada, MD*

▪ **Abstract 504:** Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.

*Nadia Harbeck - Presented by Sana Al-Sukhun, MD*

▪ **Abstract 508:** Mastectomy rates in relation to adoption of a margin guideline.

*Monica Morrow - Presented by Jaber Abbas, MD*

### 10:30 - 11:00 COFFEE BREAK

## Saturday July 15, 2017

### 11:00 - 12:00 Breast Cancer - Metastatic

*Speakers: Ahmad Awada, MD - Sana Al-Sukhun, MD - Nagi El Saghir, MD - Georges Chahine, MD*

*Chairs: Ghazi Nsouli, MD - Faeq Madanat, MD - Bassem Morqus, MD - Mahmoud Wehbe, MD*

▪ **Abstract LBA4:** OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

*Mark Robson - Presented by Sana Al-Sukhun, MD*

▪ **Abstract 1000:** MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy.

*George Sledge - Presented by Nagi El Saghir, MD*

▪ **Abstract 1001:** Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).

*Richard Finn - Presented by Nagi El Saghir, MD*

▪ **Abstract 1008:** Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

*Sylvia Adams - Presented by Ahmad Awada, MD*

### 12:00 - 13:00 Melanoma / Skin Cancers

*Speakers: Ahmad Awada, MD - Hazem Assi, MD*

*Chairs: Mohammad Haidar, MD - Ali Youssef, MD*

▪ **Abstract 9504:** Long-term outcomes in patients (pts) with ipilimumab (ipi)-naïve advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

*Caroline Robert - Presented by Ahmad Awada, MD*

▪ **Abstract 9505:** Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).

*Georgina Long - Presented by Ahmad Awada, MD*

▪ **Abstract 9507:** Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

*Hussein Tawbi - Presented by Hazem Assi, MD*

▪ **Abstract 9508:** A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).

*Georgina Long - Presented by Ahmad Awada, MD*

## Saturday July 15, 2017

13:00 - 14:00 LUNCH BREAK

14:00 - 14:30 Patient and Survivor Care

*Speakers: Marwan Ghosn, MD - Sameh Hashem, MD - Joseph Makdessi, MD*

*Chairs: Ahmed Shammot, MD - Amal Nasser, MD - Bassem Youssef, MD - Francois Kamar, MD*

▪ **Abstract LBA2:** Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.

*Ethan Basch - Presented by Marwan Ghosn, MD*

▪ **Abstract LBA10004:** SCORAD III: Randomised non-inferiority phase III trial of single dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC).

*Peter Hoskin - Presented by Sameh Hashem, MD*

▪ **Abstract LBA10006:** American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).

*Erin Van Blarigan - Presented by Joseph Makdessi, MD*

14:30 - 15:15 Genitourinary (Prostate) Cancer

*Speakers: Toni Choueiri, MD - Osama Al-Shari, MD - Deborah Mukherji, MD*

*Chairs: Rami S. AlAzab, MD - Layal Halabi, MD - Mohammad Bulbul, MD - Hassan Ghazal, MD*

▪ **Abstract LBA3:** LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naïve prostate cancer.

*Karim Fizazi - Presented by Toni Choueiri, MD*

▪ **Abstract 5002:** A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

*Kim Chi - Presented by Toni Choueiri, MD*

▪ **Abstract LBA5003:** Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).

*Nicholas James - Presented by Deborah Mukherji, MD*

▪ **Abstract 5004:** A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

*Gerhardt Attard - Presented by Osama Al-Sharou, MD*

## Saturday July 15, 2017

15:15 - 16:00 Genitourinary (Nonprostate) Cancer

*Speakers: Toni Choueiri, MD - Joseph Kattan, MD*

*Chairs: Ali Al-Daghmin, MD - Hiba Moukkadam, MD - Elie Nemr, MD*

▪ **Abstract 4501:** Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

*Dean Bajorin - Presented by Toni Choueiri, MD*

▪ **Abstract 4502:** Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

*Peter O'Donnell - Presented by Toni Choueiri, MD*

▪ **Abstract 4507:** Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).

*Robert Motzer - Presented by Toni Choueiri, MD*

▪ **Abstract 4508:** Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.

*Bernard Escudier - Presented by Joseph Kattan, MD*

Organised by:



**Infomed**  
INTERNATIONAL FOR EVENTS

4<sup>th</sup> FLOOR, QUBIC CENTER, DAOUD AMMOUN STREET, HORSH TABET - SIN EL FIL  
P.O BOX: 90-361 BEIRUT, LEBANON | TEL: +961 1 510880/1/2/3 | FAX Ext. 121  
EMAIL: [INFOMED@INFOMEDWEB.COM](mailto:INFOMED@INFOMEDWEB.COM) | WEB: [WWW.INFOMEDWEB.COM](http://WWW.INFOMEDWEB.COM)